Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.49 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.46 |
| ▸ | WDR5 | P61964 | 8/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10054979 | 0.93 | PTGIR (0.69) | PTGIRADRA2AADRA2BADRA2CCXCR4 | |
| SCHEMBL17186490 | 0.85 | PTGIR (0.61) | PTGIRADRA2AADRA2BADRA2CCXCR4 | |
| SCHEMBL4035161 | 0.85 | PTGIR (0.61) | PTGIRADRA2AADRA2BADRA2CCXCR4 | |
| SCHEMBL10800812 | 0.85 | PTGIR (0.83) | PTGIRADRA2AADRA2BADRA2CCXCR4 | |
| SCHEMBL3169468 | 0.84 | PTGIR (0.60) | PTGIRADRA2AADRA2BADRA2CCXCR4 | |
| Hydrochloric Acid SCHEMBL18605409 | 0.83 | PTGIR (0.59) | PTGIRADRA2AADRA2BADRA2CCXCR4 | |
| SCHEMBL14599597 | 0.81 | PTGIR (0.57) | PTGIRADRA2AADRA2BADRA2CCXCR4 | |
| SCHEMBL28904914 | 0.81 | PTGIR (0.64) | PTGIRADRA2AADRA2BADRA2CWDR5 | |
| SCHEMBL7430405 | 0.79 | MLLT1 (0.56) | PTGIRADRA2AADRA2BADRA2CMLLT1 | |
| SCHEMBL8152769 | 0.78 | WDR5 (0.69) | PTGIRWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635821-B1 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2009-07-08 | — | — | EP | claimed |
| US-20070123531-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | claimed |
| US-20050032868-A1 | Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | claimed |
| EP-1635821-B1 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20070123531-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | disclosed |
| US-20050032868-A1 | Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123531-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, LTB4R | PTGIR 39/4885ADRA2A 179/4885ADRA2B 47/4885 |
| US-20050032868-A1 | Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | PTGIR 57/4885ADRA2A 288/4885ADRA2B 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.